Publishing date: July 2019
Chair: Julián Garcia-Feijoo
Co-chair: Keith Barton
1. Ongoing projects
The European Glaucoma Society (EGS) has partnered with the International Glaucoma Surgery Registry (IGSR) to provide members with a secure, easy-to-use, web-based tool to monitor surgical outcomes.
Launched at the EGS Congress in 2018, the registry allows users to capture and analyse their glaucoma surgery outcomes. Users can track conventional surgery, laser, and minimally invasive glaucoma surgery procedures. The registry provides the ability to instantly graph results and will allow generation of self-audits as well as anonymous benchmarking against registry averages. The registry provides a mechanism to collect high-quality longitudinal data about treatment practices and outcomes in people undergoing glaucoma surgery. By collecting uniform data to evaluate specified outcomes, the registry will provide a real-world view of clinical practice, patient outcomes, safety, and comparative effectiveness of glaucoma procedures. To date, 117 users in over 20 countries have captured 9,506 episodes of care for patients undergoing glaucoma surgery. The registry is free to join and members can register at www.eugs.org/registry.
2. Provide a relevant breakthrough in the field
Primary Selective Laser Trabeculoplasty for Open Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success and Safety from the Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial.
Garg A, Vickerstaff V, Nathwani N, Garway-Heath D, Konstantakopoulou E, Ambler G, Bunce C, Wormald R, Barton K, Gazzard G, LiGHT Trial Study Group.
Ophthalmology. 2019 Apr 24
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M; LiGHT Trial Study Group.
Lancet. 2019 Apr 13;393(10180):1505-1516
These relevant papers could change clinical practice. The results are based on the results of a randomised clinical trial and provide evidence in favour of selective laser trabeculoplasty (SLT) as a first-line treatment for primary open-angle glaucoma and ocular hypertension. The papers support the use of SLT as first line treatment in a subset of the patients. This evidence will have an impact on the current algorithm of glaucoma treatment.
The search for EGS goal of “Paving the Way to Better Glaucoma Care” continues together with Outcome and other EGS Committees as well as SIGs, i.e. how to promote the best possible well-being and minimal glaucoma-induced visual disability in individuals with glaucoma within affordable healthcare systems.
The views expressed are those of the author(s) and are not necessarily those of the EGS.
SIG Corner editor: João Barbosa Breda